Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05613270

Characterizing Breast Cancer With 18F-FES PET/CT

Conditions: Breast Cancer

Sex: Female
Ages: 18 Years – 80 Years
Phase: NA
Enrollment: 50
Sponsor: Peking Union Medical College Hospital

Location: China

Summary

18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.

Eligibility Criteria

Inclusion Criteria:suspected or confirmed metastatic ER-positive breast cancer;18F-FDG PET/CT within two weeks;signed written consent.Exclusion Criteria:pregnancy;breastfeeding;any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05613270). StuddyBuddy aggregates publicly available trial information.